(Q42651607)

English

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

Fenghua Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yang Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hongyun Zhao

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Likun Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yan-Xia Shi

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Li Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

4 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

331-335

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9451-1

21 January 2018

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-010-9451-1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42651607&oldid=2205580451"